Key Takeaways
- DSIP is a nine-amino-acid peptide first characterized in rabbit sleep experiments in 1977.
- The original double-blind rabbit study reported greater delta and spindle EEG activity after intraventricular exposure to synthetic DSIP.
- A separate 1977 rabbit experiment reported blood-brain barrier passage, but that finding is not a universal human pharmacokinetic result.
- Historical human studies were very small and produced mixed findings: some reported sleep changes, while others found little clinical significance or weak effects unlikely to provide major benefit.
- A 2006 review called DSIP a “still unresolved riddle” because its natural precursor, gene, receptor, and relationship to sleep remained poorly characterized.
- BioPharma DSIP 5mg is laboratory research material only, not a human or veterinary product.
DSIP peptide research began with an unusual 1977 rabbit experiment and remains biologically unresolved. The synthetic nonapeptide increased delta and spindle EEG patterns in the founding study, but later sleep research did not produce a consistent clinical picture. Small historical human studies reported a mixture of positive, weak, and non-significant findings. A critical 2006 review also emphasized that the natural source, biosynthetic precursor, receptor, and sleep relationship had not been securely established.
Research boundary: This evidence review is for scientific education only. BioPharma compounds are for laboratory and research use only, not for human or veterinary use. Nothing below provides dosing, route, administration, treatment, efficacy, or safety guidance.
What Is DSIP?
Delta sleep-inducing peptide, abbreviated DSIP, is the name given to a short peptide isolated during experiments on rabbit sleep physiology. The original 1977 paper reported the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, commonly written in one-letter notation as WAGGDASGE.
Why DSIP is called a nonapeptide
A nonapeptide contains nine amino-acid residues. That structural label describes length; it does not establish a receptor, biological role, clinical effect, or endogenous production pathway. Those questions require separate evidence.
Why the name can overstate what is known
“Sleep-inducing” reflects the founding observation, not a settled universal function. The name can make the evidence sound more conclusive than it is. Later experiments produced conflicting sleep results, and the 2006 review by Kovalzon and colleagues characterized the DSIP-sleep hypothesis as weak and poorly documented.
How Was DSIP Discovered in 1977?
The foundational Proceedings of the National Academy of Sciences paper described a peptide isolated from rabbits and then synthesized for controlled testing. Researchers compared synthetic DSIP with possible metabolic fragments, sequence-modified analogues, and a related tripeptide. The experiments used 58 rabbits including controls and were evaluated under double-blind conditions.
Among the nine tested synthetic peptides, DSIP produced the reported specific enhancement of delta and spindle EEG patterns after intraventricular infusion. This was a carefully controlled animal observation for its era. It did not show that DSIP is an established human sleep regulator or that the same effect follows every material, model, or exposure condition.
What the founding experiment measured
The investigators recorded EEG leads from neocortex and archicortex and analyzed frequency patterns. Their endpoint was electrophysiological: increased delta and spindle activity. EEG pattern changes are not interchangeable with a modern clinical outcome such as durable improvement in insomnia, daytime function, or long-term safety.
Can DSIP Cross the Blood-Brain Barrier?
A second 1977 paper reported that synthetic DSIP crossed the blood-brain barrier in free-moving rabbits. The conclusion was based on increased cortical delta activity and decreased motor activity after an experimental intravenous exposure, with observations extending over five hours.
This source is useful but narrow. It concerned rabbits, one experimental setup, and indirect functional evidence. It did not provide modern human absorption, distribution, metabolism, or elimination data. The defensible conclusion is that blood-brain barrier passage was reported in that rabbit model—not that every DSIP preparation has a known human brain exposure profile.
Why DSIP Biology Is Still Unresolved
The receptor question
The 2006 Journal of Neurochemistry review stated that a possible DSIP receptor had not been isolated. Without a defined receptor and validated signaling chain, broad mechanism claims remain hypotheses rather than a settled pathway.
The precursor and gene question
The same review highlighted the absence of an isolated DSIP gene and protein precursor. Researchers had detected DSIP-like immunoreactivity in multiple tissues, but an antibody signal resembling DSIP does not necessarily prove that the exact WAGGDASGE peptide is present or responsible for the measured biology.
DSIP-like activity may not always mean DSIP itself
Kovalzon and colleagues proposed that another DSIP-like peptide could account for at least some immunoreactivity and biological activity. They also noted that certain artificial analogues—not DSIP itself—showed significant slow-wave-sleep-promoting activity in their earlier rabbit and rat studies. This distinction makes exact material identity essential when interpreting the literature.
What Did Early Human DSIP Sleep Studies Find?
The historical human literature is not a single consistent result. It includes small studies with different designs, populations, baselines, and endpoints. Several used double-blind methods, but sample sizes were too small to support broad conclusions.
A six-volunteer crossover study reported sleep-related changes
A 1981 double-blind crossover study involved six healthy volunteers. The authors reported greater sleep time during a 130-minute observation period and changes in subsequent night-sleep measures. This was the first small human experiment, not a confirmatory trial, and its sample of four men and two women sharply limits generalization.
Two 1987 insomnia studies pointed in different directions
One placebo-controlled study in 14 people with severe chronic insomnia reported improved night sleep and daytime performance over seven nights. Another double-blind crossover report found changes in some sleep measures but no significant difference for several comparisons; baseline imbalance complicated interpretation, and the authors concluded that the improvement was of little clinical significance.
The 1992 randomized study judged the effects weak
A later double-blind matched-pairs study evaluated 16 chronic-insomnia patients over five laboratory nights. Sleep efficiency and latency favored DSIP on some objective measures, but the investigators said the statistically significant effects were weak and could partly reflect an incidental change in the placebo group. Subjective sleep quality did not change. Their conclusion was explicit: short-term DSIP treatment was unlikely to be of major therapeutic benefit.
How Strong Is the Human Sleep Evidence?
| Record | Material and model | Main reported finding | Central limitation |
|---|---|---|---|
| PMID 6895513 (1981) | Synthetic DSIP; six healthy volunteers; double-blind crossover | Reported acute and delayed sleep-related changes | First experiment; only six participants |
| PMID 3583493 (1987) | DSIP; chronic insomnia; double-blind crossover | Some sleep measures changed | Baseline imbalance and little clinical significance |
| PMID 3622582 (1987) | DSIP; 14 chronic-insomnia patients; placebo-controlled | Reported improved night sleep and daytime performance | Very small, short historical study |
| PMID 1299794 (1992) | DSIP; 16 chronic-insomnia patients; randomized double-blind study | Some objective measures favored DSIP | Weak effects, possible placebo-group artifact, no subjective sleep-quality change |
The table shows why both promotion and blanket dismissal would be inaccurate. Positive observations exist, but they sit beside weak or non-significant results. The studies are decades old, small, and methodologically heterogeneous. They do not form a modern evidence base for a protocol or expected clinical effect.
What Did DSIP Research Find About ACTH and Cortisol?
A 1989 randomized double-blind crossover study tested synthetic DSIP and saline in 11 healthy men. Plasma ACTH-like immunoreactivity decreased for at least three hours after DSIP compared with control. However, plasma cortisol followed its normal daily decline and was not altered, and the investigators found no difference in urinary cortisol or monoamine-metabolite measurements.
This result should not be simplified to “DSIP lowers stress hormones.” The measured ACTH-like immunoreactivity changed in one small study; cortisol did not. The population included 11 healthy men, and the experiment did not establish a general stress-resistance outcome, a clinical benefit, or a complete HPA-axis mechanism.
DSIP Evidence: What Is Established and What Is Not?
| Question | What the cited evidence supports | What remains unresolved |
|---|---|---|
| Identity | A synthetic nonapeptide with sequence WAGGDASGE was characterized and tested | Natural precursor, gene, and the identity behind all DSIP-like immunoreactivity |
| Original sleep observation | Delta and spindle EEG enhancement in a controlled rabbit experiment | Consistent replication and relevance to a defined human sleep disorder |
| Blood-brain barrier | Functional evidence of passage in one rabbit experiment | Modern human pharmacokinetics and material-specific brain exposure |
| Receptor mechanism | No settled receptor pathway in the 2006 review | Validated receptor, signaling cascade, and endogenous function |
| Human sleep evidence | Several small historical controlled studies with mixed observations | Robust modern replication, durable effect, population selection, and safety |
| HPA-axis evidence | Lower ACTH-like immunoreactivity in one 11-person experiment | Clinical meaning; cortisol did not change in that study |
How Does DSIP Differ from Semax and Selank?
DSIP, Semax, and Selank are often grouped as CNS-focused research peptides, but they are not interchangeable. They have different sequences, origin stories, literature, and unresolved questions. BioPharma’s Semax research guide reviews a synthetic ACTH-fragment-derived peptide, while the Selank evidence guide evaluates a tuftsin-derived heptapeptide. A shared “neuropeptide” label does not permit evidence transfer between them.
The Kisspeptin research guide provides another contrast: kisspeptin has a defined receptor and reproductive-signaling context, whereas the cited DSIP review emphasizes unresolved receptor and precursor biology.
Key Terms and Definitions
- Nonapeptide
- A peptide containing nine amino-acid residues.
- Delta activity
- Low-frequency EEG activity commonly associated with deep non-rapid-eye-movement sleep, though an EEG change alone is not a clinical outcome.
- Sleep spindle
- A brief pattern of rhythmic brain activity observed during non-rapid-eye-movement sleep.
- Blood-brain barrier
- A selective interface that restricts movement of many substances from blood into the central nervous system.
- Immunoreactivity
- An antibody-detected signal resembling a target; it does not always prove exact molecular identity.
- ACTH
- Adrenocorticotropic hormone, a pituitary signal involved in the hypothalamic-pituitary-adrenal axis.
- Polysomnography
- A multi-signal sleep recording method that can include EEG, eye movements, muscle activity, breathing, and other measures.
Frequently Asked Questions About DSIP Peptide Research
What does DSIP stand for?
DSIP stands for delta sleep-inducing peptide. The name came from a 1977 rabbit experiment in which the isolated and synthetic peptide increased delta and spindle EEG patterns.
What is the amino-acid sequence of DSIP?
The sequence reported in the original paper is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, often abbreviated WAGGDASGE. It contains nine amino acids, so it is a nonapeptide.
Was DSIP discovered in humans?
No. The original peptide was isolated from rabbit cerebral venous blood during an experimental sleep model. Human experiments came later and were small.
Does DSIP reliably induce delta sleep?
The original rabbit work supported that hypothesis, but later findings were inconsistent. A 2006 review concluded that the link between DSIP and sleep remained weak and poorly characterized.
Can DSIP cross the blood-brain barrier?
A 1977 experiment reported that synthetic DSIP crossed the blood-brain barrier in free-moving rabbits, based on EEG and motor-activity changes. That animal result should not be treated as universal human pharmacokinetic proof.
Has a DSIP receptor been identified?
The 2006 review described the possible receptor, natural precursor, gene, and even the identity behind some DSIP-like immunoreactivity as unresolved. A defined DSIP receptor mechanism was not established in that review.
What did early human DSIP sleep studies find?
Some very small studies reported sleep-related changes, while others found no meaningful difference or effects of little clinical significance. The evidence is old, small, and internally inconsistent.
What did the 1992 double-blind insomnia study conclude?
In 16 chronic-insomnia patients, some objective measures favored DSIP, but the authors said the effects were weak, potentially influenced by incidental placebo-group changes, and unlikely to provide major therapeutic benefit.
What did DSIP research find about ACTH and cortisol?
A randomized double-blind crossover study in 11 healthy men reported reduced plasma ACTH-like immunoreactivity after DSIP. Plasma and urinary cortisol measures were not changed.
Is DSIP the same as melatonin?
No. DSIP is a synthetic version of a nine-amino-acid peptide described in rabbit experiments. Melatonin is a different endogenous molecule with a separate receptor system and evidence base.
What are the biggest DSIP research gaps?
Major gaps include uncertain endogenous identity and biosynthesis, no clearly established receptor in the cited review, inconsistent sleep findings, very small historical human samples, and limited modern replication.
Is BioPharma DSIP 5mg intended for human use?
No. BioPharma lists DSIP 5mg for laboratory and research use only. The vial amount is not a dose, protocol, route, administration instruction, or treatment recommendation.
Sources
- Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. PNAS. 1977. PMID 265572.
- Transport of the synthetic peptide DSIP through the blood-brain barrier in rabbit. Experientia. 1977. PMID 590449.
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006. PMID 16539679.
- Acute and delayed effects of DSIP on human sleep behavior. 1981. PMID 6895513.
- Study of DSIP efficacy in improving sleep on short-term administration to chronic insomniacs. 1987. PMID 3583493.
- Effects of DSIP on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology. 1987. PMID 3622582.
- Effects of DSIP on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology. 1992. PMID 1299794.
- Reduction of immunoreactive ACTH in plasma following DSIP in man. Psychoneuroendocrinology. 1989. PMID 2554357.
DSIP Research Material at BioPharma
Qualified laboratories can review BioPharma DSIP 5mg research material, browse the Nootropics Research catalog, or use BioPharma’s research peptides guide and certificate-of-analysis guide for broader material-evaluation context. Catalog availability does not imply a protocol, clinical indication, dose, route, treatment, or expected outcome.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. BioPharma does not provide dosing, route, administration, treatment, efficacy, or safety guidance.
